FDA approves oral medicine to treat ``postpartum depression'' that develops symptoms of depression after childbirth



Oral drug `` Zranolone '' to alleviate the symptoms of `` postpartum depression '' in which psychological disorders occur for several weeks to several months after childbirth due to hormonal imbalance in a woman's body due to childbirth. (FDA) approved the first oral medication for postpartum depression on August 4, 2023.

FDA Approves First Oral Treatment for Postpartum Depression | FDA
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression



Sage (SAGE) Tumbles as Depression Pill Approval Omits Major Disorder - Bloomberg

https://www.bloomberg.com/news/articles/2023-08-04/biogen-sage-pill-is-first-cleared-for-postpartum-depression

5 things to know about Zurzuvae, the first postpartum depression pill : NPR
https://www.npr.org/2023/08/08/1192665598/postpartum-depression-pill-zurzuvae

According to the FDA, postpartum depression, like other forms of depression, can include feelings of grief and loss of interest in previously enjoyed activities. It may also show symptoms such as cognitive impairment, loss of energy, and suicidal ideation. The Centers for Disease Control and Prevention (CDC) reports that about 20% of postpartum women's deaths are suicides.

'Postpartum depression, like other depressions, is a serious condition that can be life-threatening at worst,' said Tiffany Falcione, director of psychiatry at the FDA's Center for Drug Evaluation and Research. 'Postpartum depression can also disrupt the relationship between mother and child, harming the child and adversely affecting the child's physical and emotional development.'

In this way, postpartum depression is a serious disease that can adversely affect both mother and baby. Until now, the only treatment for postpartum depression was injections by specialists and counseling such as cognitive-behavioral therapy. .



``The introduction of oral medications for postpartum depression would be a beneficial option for women suffering from postpartum depression,'' said Falcione.

Zranolone, an oral drug for postpartum depression developed by pharmaceutical companies Biogen and Sage Therapeutics under the trade name Zurzuvae, has been tested twice in women with postpartum depression. I was.

In the study, women who developed postpartum depression during pregnancy or within 4 weeks of giving birth were given 50 mg or 40 mg, respectively, of Drift flies or the same dose of placebo once daily for 14 days.



After 14 days of treatment, depression status was measured, and it was found that postpartum depression symptoms improved significantly in patients treated with Drift compared to those treated with placebo. Did.

It is worth noting that while most antidepressants take several weeks to take effect, the dregs showed its therapeutic effect in just a few days after taking it. ``In early people, a rapid antidepressant effect appeared after the second dose of dregs fly, that is, on the third day,'' said Christina Derigiannidis of the Feinstein Institute for Medical Research, who conducted the trial.



In addition, it was revealed that the therapeutic effect of the dart fly continued on day 42, 4 weeks after the last administration of the dart fly.

On the other hand, drowsiness, dizziness, diarrhea, malaise, and urinary tract infections are said to be the side effects of drowsiness. For safety reasons, people should refrain from driving a car for about 12 hours after taking the drug. That's what I'm talking about.

Zuluzfly will be marketed in the fourth quarter of 2023 after being approved by the US Drug Enforcement Administration (DEA) to prevent abuse.

in Science, Posted by log1r_ut